Stock ABIO ARCA BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company ARCA biopharma, Inc.

Equities

ABIO

US00211Y5069

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
3.21 USD -1.83% Intraday chart for ARCA biopharma, Inc. +2.23% +88.82%
Apr. 04 ARCA biopharma, Inc. Announces Management Changes CI
Apr. 04 ARCA biopharma, Inc. Announces Separation of Michael Bristow, Chief Executive Officer CI

Business Summary

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.

Number of employees: 5

Managers

Managers TitleAgeSince
Thomas Keuer CEO
 Chief Executive Officer 65 06-09-30
C. Dekker DFI
 Director of Finance/CFO 60 21-05-09
Sharon Perry LAW
 General Counsel - 07-12-31

Members of the board

Members of the board TitleAgeSince
Anders Hove BRD
 Director/Board Member 58 17-02-15
Robert Conway CHM
 Chairman 70 13-09-02
Linda Grais BRD
 Director/Board Member 68 07-04-30
Jacob Ma-Weaver BRD
 Director/Board Member 37 22-06-14
James Flynn BRD
 Director/Board Member 43 22-12-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 14,501,143 14,314,024 ( 98.71 %) 0 98.71 %

Shareholders

NameEquities%Valuation
Cable Car Capital LLC
27.59 %
4,000,452 27.59 % 7 M $
Cable Car Capital LLC
27.59 %
4,000,452 27.59 % 7 M $
Western Standard LLC
9.724 %
1,410,143 9.724 % 2 M $
Western Standard LLC
9.724 %
1,410,143 9.724 % 2 M $
Adage Capital Management LP
8.275 %
1,200,000 8.275 % 2 M $
Janus Henderson Investors UK Ltd.
7.448 %
1,080,107 7.448 % 2 M $
Allostery Investments LP
7.344 %
1,065,016 7.344 % 2 M $
Avidity Partners Management LP
6.896 %
1,000,000 6.896 % 2 M $
BML Capital Management LLC
4.875 %
706,930 4.875 % 1 M $
Vanguard Group, Inc. (Subfiler)
3.128 %
453,598 3.128 % 798 332 $

Company contact information

ARCA biopharma, Inc.

10170 Church Ranch Way Suite 100

80021, Westminster

+720 940 2200

http://www.arcabio.com
address ARCA biopharma, Inc.(ABIO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ARCA BIOPHARMA, INC. Stock ARCA biopharma, Inc.
+88.82% 46.55M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.39% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.61% 96.84B
ARGENX SE Stock argenx SE
-1.14% 21.48B
BIONTECH SE Stock BioNTech SE
-18.14% 20.82B
GENMAB A/S Stock Genmab A/S
-7.68% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.70% 16.81B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.89% 13.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.12% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+22.25% 11.06B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ABIO Stock
  4. Company ARCA biopharma, Inc.